# DM21-C peptide-linked maytansinoid system

Source: https://onco.cc/terms/dm21-c-maytansinoid-system/  
OnCo record `dm21-c-maytansinoid-system` (Term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

DM21-C is a peptide-linked maytansinoid system used in the investigational ADAM9-directed IMGC936 construct. Its attached component and released metabolites should be identified separately.

## Summary

The IMGC936 preclinical report describes a DM21-C maytansinoid system with a cleavable tripeptide, site-specific conjugation and loading of approximately two. Earlier peer-reviewed chemical work studied peptide-cleavable self-immolative maytansinoids with different side chains and stereochemistry. That design family should not be collapsed into DM1 or DM4.

A 2019 conference abstract reports DM51 as a major released catabolite of its DM21-C conjugates by LC-MS. That conference observation does not make DM51 an alias for the attached DM21-C system or identify every compound number in related papers. The IMGC936 phase 1/2 registry is completed and has posted results; no patient-benefit estimate is inferred here from the preclinical report or registry state.

## Fields

- Kind: Term
- Last checked: 2026-11-09
- Also known as: DM21-C

### Scoped source observations

```json
{
  "chemicalObservations": [
    {
      "sources": [
        {
          "label": "IMGC936 with DM21-C: preclinical studies (2022)",
          "url": "https://pubmed.ncbi.nlm.nih.gov/35511740/"
        }
      ],
      "checkedOn": "2026-11-09",
      "species": {
        "name": "DM21-C linker-payload system"
      },
      "context": "IMGC936 preclinical design.",
      "method": "Chemical design, cell assays, xenografts and nonhuman primate studies.",
      "statement": "DM21-C is used with a cleavable tripeptide and site-specific conjugation in IMGC936.",
      "evidenceType": "experimental",
      "limitation": "The preclinical report does not establish patient benefit or a universal property of all maytansinoids.",
      "property": "chemical-identity"
    },
    {
      "sources": [
        {
          "label": "AACR 2019 abstract 538: DM21-C and DM51",
          "url": "https://doi.org/10.1158/1538-7445.AM2019-538"
        }
      ],
      "checkedOn": "2026-11-09",
      "species": {
        "name": "DM51"
      },
      "context": "Conjugates described in AACR 2019 abstract 538. This is conference evidence, not a patient outcome report.",
      "method": "LC-MS identification of a major catabolite in the reported conjugate experiments.",
      "statement": "The abstract identifies DM51 as a major released catabolite of its DM21-C conjugates.",
      "evidenceType": "conference-abstract",
      "limitation": "DM51 is not an alias for the attached DM21-C system. The Elicit DOI spelling resolved to a different canonical DOI in Crossref; that discrepancy is retained in the source receipt.",
      "property": "release"
    },
    {
      "sources": [
        {
          "label": "IMGC936 with DM21-C: preclinical studies (2022)",
          "url": "https://pubmed.ncbi.nlm.nih.gov/35511740/"
        }
      ],
      "checkedOn": "2026-11-09",
      "species": {
        "name": "DM21-C maytansinoid system"
      },
      "conjugate": {
        "name": "IMGC936"
      },
      "context": "The named IMGC936 product or preparation described by the source.",
      "method": "Design and characterisation of the preclinical site-specific construct.",
      "statement": "The preclinical report describes loading of approximately two.",
      "evidenceType": "experimental",
      "limitation": "This report does not assign a loading constant to every construct carrying this cargo or infer a patient dose.",
      "property": "conjugate-loading"
    }
  ]
}
```

## Sources

- IMGC936 with DM21-C: preclinical studies (2022): https://pubmed.ncbi.nlm.nih.gov/35511740/
- Peptide-cleavable self-immolative maytansinoid conjugates (2019): https://pubmed.ncbi.nlm.nih.gov/31620224/
- AACR 2019 abstract 538: DM21-C and DM51, conference evidence: https://doi.org/10.1158/1538-7445.AM2019-538
- IMGC936 registry NCT04622774, last update 15 January 2025: https://clinicaltrials.gov/study/NCT04622774

## Connected records

- terms: [Bystander effect (ADC)](https://onco.cc/terms/bystander-effect/), [Drug efflux pumps (ABC transporters)](https://onco.cc/terms/efflux-pump/), [Next-generation antibody-conjugate payloads](https://onco.cc/terms/next-generation-adc-payloads/), [Payload (ADC)](https://onco.cc/terms/payload/), [Tubulin inhibitor payloads](https://onco.cc/terms/tubulin-inhibitor-payloads/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/)

---
JSON: https://onco.cc/api/v1/entities/dm21-c-maytansinoid-system.json